David Cavanagh

Has grant

Senior Lecturer

University of Edinburgh
Country flagUnited Kingdom
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

The European Malaria Reagent Repository.

Open Date: 2012-09-03

Close Date: 2017-04-30

Grant: Close

The Edinburgh malaria reagent collections.

Open Date: 2011-09-19

Close Date: 2012-09-18

Grant: Close

Initiative on Optimizing Malaria Vaccine Lab Assays Evaluation

Open Date: 2009-04-01

Close Date: 2012-03-31

Grant: Close

The Tetrahymena system as an innovative approach to malaria vaccine antigen expression

Open Date: 2007-01-01

Close Date: 2010-06-30

Grant: Close

The European malaria vaccine development association

Open Date: 2006-12-01

Close Date: 2012-05-31

Articles (2)

Even within a single protein, antibody binding can have beneficial, neutral, or harmful effects during the response to infection. Resolving a polyclonal antibody repertoire across a pathogen’s proteome to specific epitopes may therefore explain much of the heterogeneity in susceptibility to infectious disease. However, the three-dimensional nature of antibody-epitope interactions makes the discovery of non-obvious targets challenging. We implemented a novel computational method and synthetic biology pipeline for identifying epitopes that are functionally important in the SARS-CoV-2 proteome and identified an IgM-dominant response to an exposed Membrane protein epitope which to our knowledge is the strongest correlate of severe disease identified to date (adjusted OR 72.14, 95% CI: 9.71 – 1300.15), stronger even than the exponential association of severe disease with age. We also identify persistence (> 2 years) of this IgM response in individuals with longCOVID, and a correlation with fatigue and depression symptom burden. The repetitive arrangement of this epitope and the pattern of isotype class switching is consistent with this being a previously unrecognized T independent antigen. These findings point to a coronavirus host-pathogen interaction characteristic of severe virus driven immune pathology. This epitope is a promising vaccine and therapeutic target as it is highly conserved through SARS-CoV-2 variant evolution in humans to date and in related coronaviruses (e.g. SARS-CoV), showing far less evolutionary plasticity than targets on the Spike protein. This provides a promising biomarker for longCOVID and a target to complement Spike-directed vaccination which could broaden humoral protection from severe or persistent disease or novel coronavirus spillovers.

Year:

2024

Even within a single protein, antibody binding can have beneficial, neutral, or harmful effects during the response to infection. Resolving a polyclonal antibody repertoire across a pathogen’s proteome to specific epitopes may therefore explain much of the heterogeneity in susceptibility to infectious disease. However, the three-dimensional nature of antibody-epitope interactions makes the discovery of non-obvious targets challenging. We implemented a novel computational method and synthetic biology pipeline for identifying epitopes that are functionally important in the SARS-CoV-2 proteome and identified an IgM-dominant response to an exposed Membrane protein epitope which to our knowledge is the strongest correlate of severe disease identified to date (adjusted OR 72.14, 95% CI: 9.71 – 1300.15), stronger even than the exponential association of severe disease with age. We also identify persistence (> 2 years) of this IgM response in individuals with longCOVID, and a correlation with fatigue and depression symptom burden. The repetitive arrangement of this epitope and the pattern of isotype class switching is consistent with this being a previously unrecognized T independent antigen. These findings point to a coronavirus host-pathogen interaction characteristic of severe virus driven immune pathology. This epitope is a promising vaccine and therapeutic target as it is highly conserved through SARS-CoV-2 variant evolution in humans to date and in related coronaviruses (e.g. SARS-CoV), showing far less evolutionary plasticity than targets on the Spike protein. This provides a promising biomarker for longCOVID and a target to complement Spike-directed vaccination which could broaden humoral protection from severe or persistent disease or novel coronavirus spillovers.

Year:

2024

Collaborators (10)

Susanna Dunachie

Professor at University of Oxford

University of Oxford

UNITED KINGDOM
View details

Patrick Kearns

ECAT/Wellcome Trust Clinical Lecturer

University of Edinburgh

UNITED KINGDOM
View details

Julian Knight

University of Oxford

UNITED KINGDOM
View details

Teresa Lambe

University of Oxford

UNITED KINGDOM
View details

Joseph Marsh

University of Edinburgh

UNITED KINGDOM
View details

Nick Gilbert

Principal Investigator

University of Edinburgh

UNITED KINGDOM
View details

Tracy Hussell

The University of Manchester

UNITED KINGDOM
View details

Alexander Mentzer

Principal Investigator / Clinical Research Scientist

University of Oxford

UNITED KINGDOM
View details

Susan Rosser

Professor of Synthetic Biology

University of Edinburgh

UNITED KINGDOM
View details

Madhvi Menon

The University of Manchester

UNITED KINGDOM
View details